INAB today
$0.87-$0.03 (-3.14%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourDescending Triangle
15 minBearish
5 minConsolidating
Daily trend turns up above $1.46
Key levels
Resistance$1.24
Resistance$1.05
Support$0.87
Latest news & SEC filings
EarningsIN8bio Posts Q3 2026 Results, Outlines Business Updates
GuidanceIN8bio plans initial INB-619 in vivo data by end of year, Q3 cash $14.0M
SEC FilingIn8Bio, Inc. filed a report on a major company event (Form 8-K)
All INAB news →About IN8bio
IN8bio develops cell-based treatments that use gamma-delta T cells, a type of immune cell, to fight tumors and immune system disorders. Its technology spans donor-derived, patient-derived, gene-edited and stem-cell-derived cell products, plus engineered molecules that redirect these immune cells toward diseased targets. Its most advanced programs address blood cancers such as leukemia and brain tumors such as glioblastoma, with earlier work aimed at autoimmune conditions. The company is based in the United States and runs its studies at medical centers there.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
IN8BIO, INC. (INAB)
What Is the Price Target for INAB?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is INAB a Buy or Sell Right Now?
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for INAB.
Start Free Trial →Is INAB Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B
Fair Value
$2.46
12
Moat Score
NONE
4/9
Piotroski Score
-6.7
Altman Z-Score
What Is Smart Money Doing with INAB?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| FAIRBAIRN EMILY | director | Sale | 724,637 | - | May 27, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →INAB Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
73.96%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for INAB
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for INAB, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:09:32 | $0.90 | 1,000 | $$900 | BUY |
| 14:31:47 | $0.99 | 3,500 | $$3K | SELL |
| 20:39:15 | $0.95 | 3,500 | $$3K | SELL |
| 20:39:13 | $0.95 | 2,500 | $$2K | SELL |
| 20:18:02 | $0.95 | 5,400 | $$5K | SELL |
5 dark pool trades shown · $$15K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for IN8BIO, INC. (INAB) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →INAB — frequently asked questions
What is INAB stock price today?
IN8BIO, INC. (INAB) is at $0.87, down 3.14% (-$0.03) at the Nov 11, 2026 close.
Why is INAB stock moving today?
Latest INAB news — Nov 7, 2026: IN8bio Posts Q3 2026 Results, Outlines Business Updates · Nov 5, 2026: IN8bio plans initial INB-619 in vivo data by end of year, Q3 cash $14.0M
What do analysts rate INAB?
Analyst ratings for INAB: 3 Buy, 0 Hold, 0 Sell — consensus Strong Buy.
Did INAB beat earnings?
INAB last reported on Aug 6, 2026: EPS -$0.25 vs -$0.34 expected — a beat of 27.3%.
Does INAB pay a dividend?
INAB does not currently pay a dividend.
What are INAB support and resistance levels?
Support: $0.87. Resistance: $1.05, $1.24, $1.35.
What are insiders doing with INAB?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on INAB?
Nov 7, 2026: IN8bio Posts Q3 2026 Results, Outlines Business Updates · Nov 5, 2026: IN8bio plans initial INB-619 in vivo data by end of year, Q3 cash $14.0M · Nov 5, 2026: In8Bio, Inc. filed a report on a major company event (Form 8-K)